Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study.
Yosuke KorokiMasataka TaguriPublished in: Targeted oncology (2022)
ClinicalTrials.gov, NCT01715285, registered 26 October, 2012.